Researcher:
Karakuş, Kağan Ege

Profile Picture
ORCID

Job Title

Undergraduate Student

First Name

Kağan Ege

Last Name

Karakuş

Name

Name Variants

Karakuş, Kağan Ege

Email Address

Birth Date

Filters

2020 - 20227

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.a5d44895-571c-4d14-8b23-d989c8986411

Search Results

Now showing 1 - 7 of 7
  • Placeholder
    PublicationMetadata only
    The my friend diabetes carbohydrate bolus calculator: user experiences
    (Mary Ann Liebert, Inc, 2022) N/A; N/A; Karakuş, Kağan Ege; Gökçe, Tuğba; Can, Ecem; Muradoğlu, Serra Küpçüoğlu; Eviz, Elif; Yeşiltepe Mutlu, Rahime Gül; Hatun, Şükrü; Undergraduate Student; Doctor; Nurse; Doctor; N/A; Researcher; Faculty Member; Faculty Member; School of Medicine; N/A; N/A; N/A; School of Medicine; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; N/A; N/A; 327618; 153511; 153504
    N/A
  • Placeholder
    PublicationMetadata only
    How do bedtime snack and no snack options affect overnight glycemia in young children with diabetes: preliminary cgm results
    (Mary Ann Liebert, Inc, 2022) Ozel, H. Gokmen; N/A; Gökçe, Tuğba; Hatun, Şükrü; Karakuş, Kağan Ege; Yeşiltepe Mutlu, Rahime Gül; Muradoğlu, Serra Küpçüoğlu; Eviz, Elif; Can, Ecem; Doctor; Faculty Member; Undergraduate Student; Faculty Member; Doctor; Researcher; Other; Koç University Hospital; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; School of Medicine; Koç University Hospital; N/A; 153504; N/A; 153511; N/A; 327618
    N/A
  • Placeholder
    PublicationMetadata only
    Insulin requirements for basal and auto-correction insulin delivery in advanced hybrid closed-loop system: 4193 days’ real-world data of children in two different age groups
    (SAGE Publications Inc., 2022) N/A; N/A; Karakuş, Kağan Ege; Yeşiltepe Mutlu, Rahime Gül; Gökçe, Tuğba; Eviz, Elif; Can, Ecem; Muradoğlu, Serra Küpçüoğlu; Hatun, Şükrü; Undergraduate Student; Faculty Member; Doctor; Researcher; Nurse; Doctor; Faculty Member; School of Medicine; School of Medicine; N/A; School of Medicine; N/A; N/A; School of Medicine; N/A; N/A; Koç University Hospital; N/A; Koç University Hospital; Koç University Hospital; N/A; N/A; 153511; N/A; 327618; N/A; N/A; 153504
    Background: The insulin requirements of people with type 1 diabetes (T1D) can vary throughout the day due to factors such as biorhythm, exercise, and food intake. The MiniMed 780G system delivers micro boluses to adjust basal insulin and delivers auto-correction boluses to meet insulin needs when micro bolus increases are insufficient. Through analysis of MiniMed 780G data, this study investigates the variations in insulin requirements throughout the day. Methods: 4193 days’ pump and continuous glucose monitoring (CGM) data of 34 children using MiniMed 780G were collected from Medtronic CareLink. Micro and auto-correction boluses were analyzed on an hourly basis for two age groups: below nine years old and above nine years old. Glycemic metrics were analyzed based on International CGM consensus. Results: The mean age was 12.3 years and mean duration of diabetes was 6.1 years. The mean time in range (TIR) and glucose management indicator (GMI) were 80.5% and 6.6%, respectively. The micro bolus (basal) ratio between 05.00 and 07.00 was significantly higher than the ratio between 10.00 and 03.00 (P <.01), whereas micro bolus was significantly lower between 19.00 and 21.00 than those between 00.00 and 10.00 (P <.001). The auto-correction ratio between 21.00 and 00.00 was significantly higher than those between 03.00-17.00 (P <.001) and 19.00-21.00 (P =.008), whereas auto-correction was significantly lower between 07.00 and 10.00 than those between 10.00 and 03.00 (P <.001). The micro bolus ratio was significantly higher in children below nine years old than in children above nine years old between 21.00-00.00 (P =.026) and 00.00-03.00 (P =.003). Conclusion: The basal insulin need follows a diurnal pattern with two significantly different periods—high between 00.00 and 10.00 and low between 10.00 and 00.00. The auto-correction rates are low between 05.00 and 10.00 and show an increasing pattern peaking between 21.00 and 00.00. These findings are compatible with the dawn and reverse dawn phenomena.
  • Placeholder
    PublicationMetadata only
    Insulin requirements for basal and auto-correction insulin delivery in minimed 780g: a real-world data of children in 2 different age groups
    (Mary Ann Liebert, Inc, 2022) N/A; N/A; Karakuş, Kağan Ege; Yeşiltepe Mutlu, Rahime Gül; Eviz, Elif; Can, Ecem; Gökçe, Tuğba; Muradoğlu, Serra Küpçüoğlu; Hatun, Şükrü; Undergraduate Student; Faculty Member; Researcher; Nurse; Doctor; Doctor; Faculty Member; School of Medicine; School of Medicine; School of Medicine; N/A; N/A; N/A; School of Medicine; N/A; N/A; N/A; Koç University Hospital; Koç University Hospital; Koç University Hospital; N/A; N/A; 153511; 327618; N/A; N/A; N/A; 153504
    N/A
  • Placeholder
    PublicationMetadata only
    Sodium-glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: review of the current evidence
    (Wiley, 2021) Afsar, Barış; Ortiz, Alberto; Hornum, Mads; Covic, Adrian; Sarafidis, Pantelis; Rossing, Peter; N/A; Demiray, Atalay; Kanbay, Mehmet; Karakuş, Kağan Ege; Master Student; Faculty Member; Undergraduate Student; Graduate School of Health Sciences; School of Medicine; School of Medicine; N/A; 110580; N/A
    Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) are promising drugs to treat chronic kidney disease patients with or without diabetes mellitus (DM). Besides improving glycemic control, SGLT2i are cardioprotective and kidney protective and decrease bodyweight, serum uric acid, blood pressure, albuminuria and glomerular hyperfiltration. These effects may benefit graft function and survival in kidney transplant (KT) patients. In this review, we evaluate data on the efficacy and safety of SGLT2i for KT patients with DM. Eleven studies with 214 diabetic KT patients treated with SGLT2i have been reported. SGLT2i lowered haemoglobin A1c and bodyweight. While glomerular filtration rate may be reduced in the short-term, it remained similar to baseline after 3-12 months. In two studies, blood pressure decreased and remained unchanged in the others. There were no significant changes in urine protein to creatinine ratio. Regarding safety, 23 patients had urinary tract infections, 2 patients had a genital yeast infection, one had acute kidney injury, and one had mild hypoglycaemia. No cases of ketoacidosis or acute rejection were reported. In conclusion, the limited experience so far suggests that SGLT2i are safe in KT patients with DM, decrease bodyweight and improve glycemic control. However, some of the benefits observed in larger studies in the non-KT population have yet to be demonstrated in KT recipients, including preservation of kidney function, reduction in blood pressure and decreased proteinuria.
  • Thumbnail Image
    PublicationOpen Access
    Current understandings of the pathogenesis of type 1 diabetes: genetics to environment
    (Baishideng Publishing Group Inc, 2020) Giwa, Adebola Matthew; Ahmed, Rizwan; Omidian, Zahra; Majety, Neha; Omer, Sarah M.; Donner, Thomas; Hamad, Abdel Rahim A.; Karakuş, Kağan Ege; School of Medicine
    Type 1 diabetes (T1D) is an autoimmune disease that usually strikes early in life, but can affect individuals at almost any age. It is caused by autoreactive T cells that destroy insulin-producing beta cells in the pancreas. Epidemiological studies estimate a prevalence of 1 in 300 children in the United States with an increasing incidence of 2%-5% annually worldwide. The daily responsibility, clinical management, and vigilance required to maintain blood sugar levels within normal range and avoid acute complications (hypoglycemic episodes and diabetic ketoacidosis) and long term micro- and macro-vascular complications significantly affects quality of life and public health care costs. Given the expansive impact of T1D, research work has accelerated and T1D has been intensively investigated with the focus to better understand, manage and cure this condition. Many advances have been made in the past decades in this regard, but key questions remain as to why certain people develop T1D, but not others, with the glaring example of discordant disease incidence among monozygotic twins. In this review, we discuss the field's current understanding of its pathophysiology and the role of genetics and environment on the development of T1D. We examine the potential implications of these findings with an emphasis on T1D inheritance patterns, twin studies, and disease prevention. Through a better understanding of this process, interventions can be developed to prevent or halt it at early stages.
  • Thumbnail Image
    PublicationOpen Access
    Benefits and drawbacks of Continuous Glucose Monitoring (CGM) use in young children with type 1 diabetes: a qualitative study from a country where the CGM is not reimbursed
    (Sage, 2021) Karakuş, Kağan Ege; Sakarya, Sibel; Yeşiltepe Mutlu, Rahime Gül; Berkkan, Metehan; Muradoğlu, Serra Küpçüoğlu; Can, Ecem; Gökçe, Tuğba; Eviz, Elif; Hatun, Şükrü; Faculty Member; Researcher; Faculty Member; School of Medicine; Graduate School of Health Sciences; Koç University Hospital; N/A; 172028; 153511; N/A; N/A; N/A; N/A; 327618; 153504
    Investigating the daily life experiences of patients using Continuous Glucose Monitoring (CGM) can highlight the benefits and barriers in using this system for people with type 1 diabetes (T1D). Semi-structured qualitative interviews were conducted with the caregivers of 10 children aged <9 years, all of whom had been treated for T1D and had used CGM >6 months. These interviews were analyzed using the content analysis approach and from these interviews, four meta themes emerged: metabolic control, barriers to CGM use, CGM use in daily life, and comparison with fingersticks. Families reported the following as benefits of CGM: pain relief, better hypoglycemia and hyperglycemia management, increased control over diet and social life, reduced worries at school and during the night, and convenience in entrusting the child to the care of others. Cost, concerns related to accuracy and reliability of measurements, insertion, adhesion and removal issues all emerged as barriers to CGM use. The most prominent issue was the economic burden of CGM. Families accept this burden, even though it is challenging, as their experiences in using CGM are positive and they feel that CGM is necessary for T1D management.